Abstracts tagged "spondyloarthritis"

Abstract Number: 1016 • ACR Convergence 2022
Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis
Ivan Arias-de la Rosa¹, Elena Carnero-Montoro², lourdes Ladehesa-Pineda³, Clementina Lopez-Medina⁴, Rafaela Ortega-Castro¹, Maria del Carmen Abalos-Aguilera⁵, Daniel Dominguez-Toro⁶, Manuel Martinez-Bueno², Ruth Dominguez⁶, Olivia Castellini⁶, Guillermo Barturen², Chary López-Pedrera⁷, Eduardo Collantes¹, Marta Alarcon-Riquelme² and Nuria Barbarroja¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ⁴Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁵Hospital Universitario Reina Sofia, Cordoba, Spain, ⁶GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors could be underestimating the subclinical atherosclerosis in patients with Spondyloarthritis (SpA). The identification of subclinical CVD sings and…
Abstract Number: 1160 • ACR Convergence 2022
Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice
Jyotsna Soundararajan¹, Anu Shivalikanjli², Thomas Keane² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Overexpression of IL-23 using IL-23 minicircle DNA in B10.RIII mice results in the development of a spondyloarthritis-like disease. B10.RIII (B10.RIII-H2r H2-T18b/(71NS)SnJ) is a major…
Abstract Number: 1511 • ACR Convergence 2022
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
Dafna Gladman¹, Ghaydaa Aldabie², Fangya Ma³, Mitchell Sutton⁴, Ker-Ai Lee³ and Richard Cook³, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³University of Waterloo, Waterloo, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The majority of patients with PsA present with skin manifestations first. Several studies have examined the relationship between activity/severity of skin and joint manifestations,…
Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: L12 • ACR Convergence 2021
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function
Michaela Koehm¹, Tanja Rossmanith², Ann Christina Foldenauer², Eva Herrmann³, Herbert Kellner⁴, Uta Kiltz⁵, Jürgen Rech⁶, Gerd Burmester⁷, David Kofler⁸, Jan Brandt-Jürgens⁹, Christin Jonetzko¹⁰, Harald Burkhardt¹ and Frank Behrens¹, ¹Rheumatology Goethe-University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ³Institute for Biostatistics and Mathematical Modeling, Goethe-Universität Frankfurt, Frankfurt, Germany, ⁴Praxis Prof. Dr. Kellner, München, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, ⁷Charite Universitaetsmedizin Berlin, Germany and DRFZ, Berlin, Germany, ⁸Universitätsklinikum Köln, Med. Klinik I f. Innere Medizin Immunologische Ambulanz, Köln, Germany, ⁹Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz, Berlin, Germany, ¹⁰Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX…
Abstract Number: L15 • ACR Convergence 2021
A Predictive Diagnostic Model for IgA Vasculitis Based on a Metabolomic Approach
Alexandre Boissais¹, Hélène Blasco², Patrick Emond³, Antoine Lefevre², Adrien Bigot⁴, denis Mulleman⁵, François Maillot⁴ and Alexandra Audemard-Verger⁴, ¹Medical University of Tours, Tours, France, ²Biochemistry and Molecular Biology Department, Tours, France, ³In vitro Nuclear Medicine Department, Tours, France, ⁴Department of Internal Medicine, Tours, France, ⁵Rheumatology Department, Tours, France
Background/Purpose: IgA vasculitis is a rare systemic disease that is life-threatening mainly due to digestive or renal involvement. To date, there is no reliable diagnostic…
Abstract Number: 0051 • ACR Convergence 2021
Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
Jacqueline Lai¹, Sara Rahmati², Raam Sivakumar², Katerina Oikonomopoulou³, Fatima Abji⁴ and Vinod Chandran⁵, ¹McMaster University, Hamilton, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that currently lacks diagnostic biomarkers. We hypothesized that there are differences in the protein intensities in the…
Abstract Number: 0361 • ACR Convergence 2021
Factors Associated with Engaging in Physical Activity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, David Gálvez-Ruiz⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Physical activity is an essential component in axial spondyloarthritis (axSpA) care, improving physical and mental wellbeing. This analysis aims to identify factors associated with…
Abstract Number: 0379 • ACR Convergence 2021
Pain Sensitivity in Axial Spondyloarthritis – Comparisons Between Patients and Controls, Women and Men, and Between Different Pain Groups
Elisabet Lindqvist¹, Tor Olofsson², Stefan Bergman³, Ann Bremander⁴, Mats Geijer⁵, Lars Erik Kristensen⁶, Jack Kvistgaard Olsen⁶, Jonas Sagard⁷, Johan Karlsson Wallman⁸ and Elisabeth Mogard¹, ¹Department of Rheumatology, Skane University Hospital, Lund, Sweden, ²Lund University and Skane University Hospital, Lund, Sweden, ³Spenshult Research and Development Centre, Halmstad, Sweden, ⁴Spenshult research and development centre, Vilsharad, Sweden, ⁵University of Gothenburg, Sahlgrenska Academy, Institute of Clinical Sciences, Department of Radiology, Göteborg, Sweden, ⁶Parker Institute, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Department of Rheumatology, Copenhagen, Denmark, ⁷Skåne University Hospital, Lund, Sweden, ⁸Lund University and Skane University Hospital, Hjarup, Sweden
Background/Purpose: Chronic widespread pain (CWP) is common in axial spondyloarthritis (axSpA). For ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) patients, no differences were found in…
Abstract Number: 0901 • ACR Convergence 2021
Low Dose Dual Energy CT Scan for the Detection of Bone Marrow Edema and Erosions in Axial Spondyloarthritis
Jonathan Chan¹, Savvas Nicolaou¹, Yet Yen Yan², Mahomed Osman³, Hugue Ouellette¹ and Sabeena Jalal⁴, ¹University of British Columbia, Vancouver, BC, Canada, ²Changi General Hospital, Singapore, ³Queensland X-ray, Brisbane, Australia, ⁴Harvard School of Public Health, Boston, USA, Boston, MA
Background/Purpose: Bone marrow edema (BME) and erosions of the sacroiliac (SI) joints are key imaging features in the diagnosis of axial spondyloarthritis (axSpA). MRI with…
Abstract Number: 0929 • ACR Convergence 2021
Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare Be Predicted?
Marie Wetterslev¹, Stylianos Georgiadis², Sara Nysom Christiansen³, Susanne Juhl Pedersen², Inge Juul Sørensen⁴, Merete Lund Hetland¹, Anne Duer⁵, Mikael Boesen⁶, Kasper Kjærulf Gosvig⁷, Jakob Møllenbach Møller⁷, Mads Bakkegaard⁸, Cecilie Heegaard Brahe², Niels Steen Krogh⁹, Bente Jensen⁸, Ole Rintek Madsen⁸, Jan Christensen⁸, Annette Hansen⁸, Jesper Nørregaard⁸, Henrik Røgind⁸ and Mikkel Ostergaard¹⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Department of Radiology, Rigshospitalet, Glostrup, Copenhagen, Denmark, ⁶Department of Radiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, ⁸Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: Patients with axial spondyloarthritis (axSpA) in clinical remission tapered Tumor Necrosis Factor inhibitor (TNFi) treatment according to a clinical guideline and were followed for…
Abstract Number: 1311 • ACR Convergence 2021
De Novo Psoriasis Can Be Reported at Any Timepoint in Early Axial Spondyloarthritis: An Analysis of 6 Years of Follow-up of the DESIR Cohort
Florian LUCASSON¹, Pascal Richette², krystel aouad¹, Adeline RUYSSEN-WITRAND³, Daniel Wendling⁴, Bruno Fautrel⁵ and Laure Gossec⁶, ¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, ²Lariboisiere Hospital, Paris, France, ³Toulouse University Hospital, Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, Paul Sabatier University,, Toulouse, France, ⁴Service de rhumatologie, CHU de Besançon, Besançon, France, ⁵Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ⁶Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Psoriasis is a frequent extra-articular manifestation in axial spondyloarthritis (axSpA) with a prevalence in established axSpA around 9% and consequences on the disease course.…
Abstract Number: 1775 • ACR Convergence 2021
Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis
Timothy Kwok¹, Mitchell Sutton², Richard Cook³, Daniel Pereira⁴ and Dafna Gladman⁵, ¹Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Isolated axial involvement exists in 2 to 5% of all psoriatic arthritis (PsA) patients. However, it is currently unknown whether patients with isolated axial…
Abstract Number: 0055 • ACR Convergence 2021
Time Course of Intestinal Permeability and Intestinal Inflammation in Rat Adjuvant-induced Arthritis
Sophie Hecquet¹, Perle Totoson², Marie-Paule Algros³, Hélène Martin², Célian Peyronnel², Maude Tournier², Clement Prati¹, Daniel Wendling¹, Céline Demougeot² and Frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, ³Service d'anatomopathologie, CHU de Besançon, Besançon, France
Background/Purpose: Intestinal inflammation (I-Inf) and increased intestinal permeability (IP) and intestinal damage (ID) have been observed in patients with spondyloarthritis (SpA). However, whether these changes…
Abstract Number: 0362 • ACR Convergence 2021
Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis
Martin Rudwaleit¹, Pedro Machado², Lianne Gensler³, Vanessa Taieb⁴, Natasha de Peyrecave⁵, Bengt Hoepken⁶ and Désirée van der Heijde⁷, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with increased absence from work and reduced work productivity, which can impact employment status.1 TNF inhibitors such as certolizumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].